{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:36:04Z","timestamp":1794587764680,"version":"4.9.1"},"reference-count":35,"publisher":"The Pediatric Pharmacy Association","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"abstract":"<jats:p>\n                    Spinal muscular atrophy (SMA) encompasses a group of autosomal recessively inherited degenerative neuromuscular disorders. They range in severity from neonatal onset with rapidly progressive weakness and early mortality (SMA-1), to onset in infancy (SMA-2), to adolescent\/adult onset with indolent clinical course (SMA-3\/-4). SMA patients share mutations in the survival motor neuron (\n                    <jats:italic>SMN<\/jats:italic>\n                    ) gene; variations in clinical phenotypes are attributable to copy numbers of the closely related\n                    <jats:italic>SMN2<\/jats:italic>\n                    gene. In December 2016, the US Food and Drug Administration (FDA) approved nusinersen (Spinraza, Biogen, Cambridge, MA) to treat SMA. Nusinersen, an antisense oligonucleotide, is administered directly into cerebrospinal fluid. It alters\n                    <jats:italic>SMN2<\/jats:italic>\n                    pre-RNA splicing so exon 7 is included, increasing expression of functional SMN protein. Although nusinersen was FDA approved for treatment of all forms of SMA, the initial clinical trials were limited to patients up to age 14 years, diagnosed with SMA-1,-2, -3, not on mechanical ventilation support. Two subsequent phase 3 trials were completed for SMA-1 and SMA-2\/-3 and demonstrated improved motor milestones and event-free survival, better than expected based on natural history studies. Efficacy assessments for patients receiving nusinersen are based on serial assessments of performance on age-appropriate standardized motor scales. Treatment requires complex financial and logistics because of the very high drug cost, intrathecal administration, and medical fragility of the patients. Treatment implementation also engenders ethical considerations related to cost, insurance coverage, limited clinical data on groups of patients not in clinical trials, and questions of duration of treatment. Nusinersen has been integrated into the treatment of many SMA patients.\n                  <\/jats:p>","DOI":"10.5863\/1551-6776-24.3.194","type":"journal-article","created":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T13:06:56Z","timestamp":1557493616000},"page":"194-203","source":"Crossref","is-referenced-by-count":79,"title":["Nusinersen: A Novel Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy"],"prefix":"10.5863","volume":"24","author":[{"given":"Erin E.","family":"Neil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth K.","family":"Bisaccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3883","reference":[{"issue":"3","key":"i1551-6776-24-3-194-b1","series-title":"Ann Neurol","first-page":"355","article-title":"Emerging therapies and challenges in spinal muscular atrophy","volume":"81","year":"2017","unstructured":"Farrar\n              MA\n            , ParkSB, VucicS, \n          et al. Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol. 2017;81(3):355\u2013368."},{"issue":"4","key":"i1551-6776-24-3-194-b2","series-title":"PLoS Biol","first-page":"729","article-title":"Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon","volume":"5","year":"2007","unstructured":"Hua\n              Y\n            , VickersTA, BakerBF, \n          et al. Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon. PLoS Biol. 2007;5(4):729\u2013744."},{"issue":"6","key":"i1551-6776-24-3-194-b3","series-title":"Nat Rev Neurol","first-page":"351","article-title":"Spinal muscular atrophy\u2014recent therapeutic advances for an old challenge","volume":"11","year":"2015","unstructured":"Faravelli\n              I\n            , NizzardoM, ComiGP, \n          et al. Spinal muscular atrophy\u2014recent therapeutic advances for an old challenge. Nat Rev Neurol. 2015;11(6):351\u2013359."},{"issue":"3","key":"i1551-6776-24-3-194-b4","series-title":"Neuromuscul Disord","first-page":"208","article-title":"Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated spanish patients and a compilation of 2834 reported cases","volume":"28","year":"2018","unstructured":"Calucho\n              M\n            , BernalS, AliasL, \n          et al. Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated spanish patients and a compilation of 2834 reported cases. Neuromuscul Disord. 2018;28(3):208\u2013215."},{"issue":"8","key":"i1551-6776-24-3-194-b5","series-title":"J Child Neurol","first-page":"1027","article-title":"Consensus statement for standard of care in spinal muscular atrophy","volume":"22","year":"2007","unstructured":"Wang\n              CH\n            , FinkelRS, BertiniES, \n          et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007;22(8):1027\u20131049."},{"issue":"72","key":"i1551-6776-24-3-194-b6","series-title":"Sci Transl Med","first-page":"1","article-title":"Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy","volume":"3","year":"2011","unstructured":"Passini\n              MA\n            , BuJ, RichardsAM, \n          et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med. 2011;3(72):1\u201313."},{"issue":"8","key":"i1551-6776-24-3-194-b7","series-title":"Nat Rev Neurosci","first-page":"597","article-title":"Spinal muscular atrophy: why do low levels of SMN make motor neurons sick?","volume":"10","year":"2009","unstructured":"Burghes\n              AHM\n            , BeattieCE. Spinal muscular atrophy: why do low levels of SMN make motor neurons sick?Nat Rev Neurosci. 2009;10(8):597\u2013609."},{"key":"i1551-6776-24-3-194-b8","series-title":"Nusinersen [package insert]","year":"2018","unstructured":"Nusinersen [package insert]. Cambridge, MA: Biogen Inc; May2018."},{"issue":"4","key":"i1551-6776-24-3-194-b9","series-title":"Nat Neurosci","first-page":"497","article-title":"Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy","volume":"20","year":"2017","unstructured":"Corey\n              DR\n            \n          . Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy. Nat Neurosci. 2017;20(4):497\u2013499."},{"issue":"4","key":"i1551-6776-24-3-194-b10","series-title":"Drugs","first-page":"473","article-title":"Nusinersen: first global approval","volume":"77","year":"2017","unstructured":"Hoy\n              SM\n            \n          . Nusinersen: first global approval. Drugs. 2017;77(4):473\u2013479."},{"issue":"3","key":"i1551-6776-24-3-194-b11","series-title":"Muscle Nerve","first-page":"356","article-title":"Making sense of antisense oligonucleotides: a narrative review","volume":"57","year":"2018","unstructured":"Goyal\n              N\n            , NarayanaswamiP. Making sense of antisense oligonucleotides: a narrative review. Muscle Nerve. 2018;57(3):356\u2013370."},{"issue":"8","key":"i1551-6776-24-3-194-b12","series-title":"J Clin Pharmacol","first-page":"1031","article-title":"Population pharmacokinetics of nusinersen in the cerebral spinal fluid and plasma of pediatric patients with spinal muscular atrophy following intrathecal administrations","volume":"57","year":"2017","unstructured":"Luu\n              KT\n            , NorrisDA, GunawanR, \n          et al. Population pharmacokinetics of nusinersen in the cerebral spinal fluid and plasma of pediatric patients with spinal muscular atrophy following intrathecal administrations. J Clin Pharmacol. 2017;57(8):1031\u20131041."},{"issue":"10063","key":"i1551-6776-24-3-194-b13","series-title":"Lancet","first-page":"3017","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","year":"2016","unstructured":"Finkel\n              RS\n            , ChiribogaCA, VajsarJ, \n          et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016;388(10063):3017\u20133026."},{"issue":"6","key":"i1551-6776-24-3-194-b14","series-title":"Ann Neurol","first-page":"883","article-title":"Natural history of infantile-onset spinal muscular atrophy","volume":"82","year":"2017","unstructured":"Kolb\n              SJ\n            , CoffeyCS, YankeyJW, \n          et al. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol. 2017;82(6):883\u2013891."},{"issue":"18","key":"i1551-6776-24-3-194-b15","series-title":"N Engl J Med","first-page":"1723","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","year":"2017","unstructured":"Finkel\n              RS\n            , MercuriE, DarrasBT, \n          et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723\u20131732."},{"issue":"10","key":"i1551-6776-24-3-194-b16","series-title":"Neurology","first-page":"890","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy","volume":"86","year":"2016","unstructured":"Chiriboga\n              CA\n            , SwobodaKJ, DarrasBT, \n          et al. Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy. Neurology. 2016;86(10):890\u2013897."},{"issue":"7","key":"i1551-6776-24-3-194-b17","series-title":"N Engl J Med","first-page":"625","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","year":"2018","unstructured":"Mercuri\n              E\n            , DarrasBT, ChiribogaCA, \n          et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378(7):625\u2013635."},{"key":"i1551-6776-24-3-194-b18","article-title":"Interim efficacy and safety results from the phase 2 NURTURE study evaluating nusinersen in presymptomatic infants with spinal muscular atrophy","unstructured":"De Vivo\n              D\n            , HwuW, ReynaS, \n          et al. Interim efficacy and safety results from the phase 2 NURTURE study evaluating nusinersen in presymptomatic infants with spinal muscular atrophy. 69th American Academy of Neurology Meeting; April 22\u201327, 2017; Boston, MA. Abstract S46.003."},{"issue":"10","key":"i1551-6776-24-3-194-b19","series-title":"Expert Rev Neurother","first-page":"955","article-title":"Nusinersen for the treatment of spinal muscular atrophy","volume":"17","year":"2017","unstructured":"Chiriboga\n              CA\n            \n          . Nusinersen for the treatment of spinal muscular atrophy. Expert Rev Neurother. 2017;17(10):955\u2013962."},{"key":"i1551-6776-24-3-194-b20","series-title":"Ther Adv Neurol Disord","first-page":"1","article-title":"Nusinersen for spinal muscular atrophy","volume":"11","year":"2018","unstructured":"Wurster\n              CD\n            , LudolphAC. Nusinersen for spinal muscular atrophy. Ther Adv Neurol Disord. 2018;11:1\u20133."},{"issue":"1","key":"i1551-6776-24-3-194-b21","series-title":"Muscle Nerve","first-page":"142","article-title":"Motor milestone assessment of infants with spinal muscular atrophy using the Hammersmith infant neurological exam\u2014part 2: experience from a nusinersen clinical study","volume":"57","year":"2018","unstructured":"Bishop\n              KM\n            , MontesJ, FinkelRS. Motor milestone assessment of infants with spinal muscular atrophy using the Hammersmith infant neurological exam\u2014part 2: experience from a nusinersen clinical study. Muscle Nerve. 2018;57(1):142\u2013146."},{"issue":"11","key":"i1551-6776-24-3-194-b22","series-title":"Neuromuscul Disord","first-page":"754","article-title":"Developmental milestones in type I spinal muscular atrophy","volume":"26","year":"2016","unstructured":"De Sanctis\n              R\n            , CorattiG, PasternakA, \n          et al. Developmental milestones in type I spinal muscular atrophy. Neuromuscul Disord. 2016;26(11):754\u2013759."},{"issue":"2","key":"i1551-6776-24-3-194-b23","series-title":"Ann Clin Trans Neurol","first-page":"132","article-title":"Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study","volume":"3","year":"2016","unstructured":"Kolb\n              SJ\n            , CoffeyCS, YankeyJW, \n          et al. Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study. Ann Clin Trans Neurol. 2016;3(2):132\u2013145."},{"issue":"3","key":"i1551-6776-24-3-194-b24","series-title":"Neuromuscul Disord","first-page":"155","article-title":"The Children's Hospital of Philadelphia infant test of neuromuscular disorders (CHOP INTEND): test development and reliability","volume":"20","year":"2010","unstructured":"Glanzman\n              AM\n            , MazzoneE, MainM, \n          et al. The Children's Hospital of Philadelphia infant test of neuromuscular disorders (CHOP INTEND): test development and reliability. Neuromuscul Disord. 2010;20(3):155\u2013161."},{"issue":"4","key":"i1551-6776-24-3-194-b25","series-title":"Pediatr Phys Ther","first-page":"322","article-title":"Validation of the Children's Hospital of Philadelphia infant test of neuromuscular disorders (CHOP INTEND)","volume":"23","year":"2011","unstructured":"Glanzman\n              AM\n            , McDermottMP, MontesJ, \n          et al. Validation of the Children's Hospital of Philadelphia infant test of neuromuscular disorders (CHOP INTEND). Pediatr Phys Ther. 2011;23(4):322\u2013326."},{"issue":"1","key":"i1551-6776-24-3-194-b26","series-title":"BMC Neurol","first-page":"39","article-title":"Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy","volume":"17","year":"2017","unstructured":"Pera\n              MC\n            , CorattiG, ForcinaN, \n          et al. Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy. BMC Neurol. 2017;17(1):39. doi: 10.1186\/s12883-017-0790-9."},{"issue":"9\u201310","key":"i1551-6776-24-3-194-b27","series-title":"Neuromuscul Disord","first-page":"693","article-title":"An expanded version of the Hammersmith functional motor scale for SMA II and III patients","volume":"17","year":"2007","unstructured":"O'Hagen\n              JM\n            , GlanzmanAM, McDermottMP, \n          et al. An expanded version of the Hammersmith functional motor scale for SMA II and III patients. Neuromuscul Disord. 2007;17(9\u201310):693\u2013697."},{"key":"i1551-6776-24-3-194-b28","article-title":"Expanded Hammersmith functional motor scale for SMA (HFMSE)","unstructured":"Expanded Hammersmith functional motor scale for SMA (HFMSE). http:\/\/columbiasma.org\/docs\/cme-2010\/Hammersmith%20Functional%20Motor%20Scale%20Expanded%20for%20SMA%20Type%20II%20and%20III%20-%20Manual%20of%20Procedures.pdf. Accessed March 19, 2019."},{"issue":"8","key":"i1551-6776-24-3-194-b29","series-title":"PLoS One","first-page":"e12140","article-title":"SMA CARNIVAL trial part 1: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy","volume":"5","year":"2010","unstructured":"Swoboda\n              KJ\n            , ScottCB, CrawfordTO, \n          et al. SMA CARNIVAL trial part 1: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy. PLoS One. 2010;5(8):e12140. doi: 10.1371\/journal.pone.0012140."},{"issue":"9","key":"i1551-6776-24-3-194-b30","series-title":"Clin Drug Investig","first-page":"807","article-title":"Nusinersen: the first option beyond supportive care for spinal muscular atrophy","volume":"37","year":"2017","unstructured":"Maharshi\n              V\n            , HasanS. Nusinersen: the first option beyond supportive care for spinal muscular atrophy. Clin Drug Investig. 2017;37(9):807\u2013817."},{"issue":"2","key":"i1551-6776-24-3-194-b31","series-title":"JAMA Pediatr","first-page":"188","article-title":"Ethical challenges confronted when providing nusinersen treatment for spinal muscular atrophy","volume":"172","year":"2018","unstructured":"Burgart\n              AM\n            , MagnusD, TaborHK, \n          et al. Ethical challenges confronted when providing nusinersen treatment for spinal muscular atrophy. JAMA Pediatr. 2018;172(2):188\u2013192."},{"issue":"9","key":"i1551-6776-24-3-194-b32","series-title":"J Neurol Neurosurg Psychiatry","first-page":"937","article-title":"Nusinersen for SMA: expanded access programme","volume":"89","year":"2018","unstructured":"Farrar\n              MA\n            , TeohHL, CareyKA, \n          et al. Nusinersen for SMA: expanded access programme. J Neurol Neurosurg Psychiatry. 2018;89(9):937\u2013942."},{"key":"i1551-6776-24-3-194-b33","series-title":"Ther Adv Neurol Disord","first-page":"1","article-title":"Advances in spinal muscular atrophy therapeutics","volume":"11","year":"2018","unstructured":"Parente\n              V\n            , CortiS. Advances in spinal muscular atrophy therapeutics. Ther Adv Neurol Disord. 2018;11:1\u201313."},{"key":"i1551-6776-24-3-194-b34","series-title":"Handbook of Clinical Neurology","first-page":"591","article-title":"Spinal muscular atrophy","year":"2018","unstructured":"Arnold\n              ES\n            , FischbeckKH. Spinal muscular atrophy. In: GeschwindDH, PaulsonHL, KleinC, eds. Handbook of Clinical Neurology. Neurogenetics, Part II, Vol. 148. 3rd series. Cambridge, MA: Elsevier; 2018:591\u2013601."},{"issue":"18","key":"i1551-6776-24-3-194-b35","series-title":"N Engl J Med","first-page":"1713","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","year":"2017","unstructured":"Mendell\n              JR\n            , Al-ZaidyS, ShellR, \n          et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713\u20131722."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/24\/3\/article-p194.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/jppt\/article-pdf\/24\/3\/194\/2467066\/1551-6776-24_3_194.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/24\/3\/article-p194.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/24\/3\/article-p194.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T20:42:00Z","timestamp":1747341720000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/24\/3\/article-p194.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":35,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-24.3.194","relation":{},"ISSN":["1551-6776"],"issn-type":[{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}